Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1701963 + Irinotecan in KRAS+ Colorectal Cancer
NCT04627142Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 1701963 in colorectal cancer (CRC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum tolerated dose at 28 days, Number of patients experiencing DLTs at 28 days and 1 more. Started Nov 2020; status: terminated.
02
Drugs
BI 1701963
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04627142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627142.